Potential Revenue
Revenue Potential for ALVIZON™: ~ $US2.0 bn for GA alone.
- Addressable Market: 25m people expected to grow to 35m by 2035.
- This represents 15% of the estimated worldwide population afflicted by AMD.
- Revenue potential by 2035:
- Sales of 3.0 to 4.2 million vials of ALVIZON
- Assuming a simultaneous global launch in 2032 and an adoption by 3% of the addressable market, each receiving 4 treatments per annum.
- Revenue of ~US$ 2.0 bn by 2035
- Assuming a unit price per vial of US$470.00.
- Sales of 3.0 to 4.2 million vials of ALVIZON
Why ALVIZON™?
The key clinical advantages of ALVIZON™ include:
- Improved retinal anatomy and function.
- Improved visual acuity.
- No evidence of sustained increase in IOP or cataractogenesis.
- Significant inhibition in the rate of GA lesion spread.
- No evidence of refractility.
- Patents have been granted in over 30 countries for its use in Dry-AMD and GA.